6JamesS.T.Yao William H.Pearce.Pracitical Vascular Surgery[M].北京:科学出版社,2000.427-439. 被引量：1
7Levine MN,Hirsh J,Gent M,et al Double-blind randomized trial of very-low-dose warfarin for prevention of thromboembolism in stage Ⅳ breast cancer[J].Lancet,1994,343(8902):886 被引量：1
二级参考文献26
1[1]Kubota T,Andoh K,Sedakata H,et al.Tissue factor released from leukemic cells[J].Thromb Haemostas,1991,65(1):59-63. 被引量：1
2[2]Gordon SG,Benson B.Analysis of serum cancer procoagulant activity and its possible use as a tumor marker[J].Thromb Res,1989,56(3):431-440. 被引量：1
3[3]Noguchi M,Sakai T,Kisiel W.Identification and partial purification of a novel tumor-derived protein that induces tissue factor on cultured human endothelial cells[J].Biochem Biophys Res Commun,1989,160(1):222-227. 被引量：1
4[4]Naschitz JE,Yeshurun D,Lev LM.Thromboembolism in cancer: changing trends[J].Cancer,1993,71(4):1384-1390. 被引量：1
5[5]Levine MN.Prevention of thrombotic disorders in cancer patients undergoing chemotherapy[J].Thromb Haemostas,1997,78(1):133-136. 被引量：1
6[6]AL-Mondhiry H.Betathromboglobulin and platelet factor 4 in patients with cancer: correlation with the stage of disease and the effect of chemotherapy[J].Am J Heamatol,1983,14(2):105-165. 被引量：1
8[8]Grignani G,Paccdhiarini L,Pagliarino M.The possible role of bloos platelets in tumour growth and dissemination[J].Haematologica,1986,71(3):245-55. 被引量：1
9[9]Kwaan HC,Keet HN.Fibrinolysis and cancer[J].Semin Thromb Hemost,1990,16(3):230-235. 被引量：1
10[10]Newland RJ,Haire WD.Elevated plasminogen activator inhibitor levels found in patients with malignant conditions[J].Am J Clin Pathol,1991,96(5):602-604. 被引量：1
